SE9702680D0 - New formulation - Google Patents

New formulation

Info

Publication number
SE9702680D0
SE9702680D0 SE9702680A SE9702680A SE9702680D0 SE 9702680 D0 SE9702680 D0 SE 9702680D0 SE 9702680 A SE9702680 A SE 9702680A SE 9702680 A SE9702680 A SE 9702680A SE 9702680 D0 SE9702680 D0 SE 9702680D0
Authority
SE
Sweden
Prior art keywords
pct
new formulation
sec
date
pub
Prior art date
Application number
SE9702680A
Other languages
English (en)
Inventor
Joanne Broadhead
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9702680(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Priority to SE9702680A priority Critical patent/SE9702680D0/sv
Publication of SE9702680D0 publication Critical patent/SE9702680D0/sv
Priority to TW087109890A priority patent/TW585764B/zh
Priority to NZ502073A priority patent/NZ502073A/en
Priority to BR9810703-8A priority patent/BR9810703A/pt
Priority to DK98934017T priority patent/DK1000079T3/da
Priority to CZ20000083A priority patent/CZ298110B6/cs
Priority to CN98807089A priority patent/CN1263533A/zh
Priority to HU0002622A priority patent/HU226489B1/hu
Priority to DE69836023T priority patent/DE69836023T2/de
Priority to EEP200000022A priority patent/EE04119B1/xx
Priority to IL13386898A priority patent/IL133868A0/xx
Priority to RU2000103216/14A priority patent/RU2216330C2/ru
Priority to AU83625/98A priority patent/AU8362598A/en
Priority to ZA985669A priority patent/ZA985669B/xx
Priority to CNA2006100092846A priority patent/CN1864696A/zh
Priority to ES98934017T priority patent/ES2273425T3/es
Priority to IDW20000028A priority patent/ID24716A/id
Priority to PT98934017T priority patent/PT1000079E/pt
Priority to KR1020007000205A priority patent/KR100786654B1/ko
Priority to SK1836-99A priority patent/SK285766B6/sk
Priority to UA2000010491A priority patent/UA65576C2/uk
Priority to JP2000502063A priority patent/JP4950380B2/ja
Priority to PL337970A priority patent/PL192768B1/pl
Priority to EP98934017A priority patent/EP1000079B1/en
Priority to AT98934017T priority patent/ATE340801T1/de
Priority to SI9830865T priority patent/SI1000079T1/sl
Priority to TR2000/00006T priority patent/TR200000006T2/xx
Priority to CA002295628A priority patent/CA2295628C/en
Priority to US09/125,165 priority patent/US6130208A/en
Priority to PCT/SE1998/001287 priority patent/WO1999002542A1/en
Priority to ARP980103182A priority patent/AR013157A1/es
Priority to MYPI98003170A priority patent/MY116421A/en
Priority to SA98190328A priority patent/SA98190328B1/ar
Priority to IS5331A priority patent/IS2439B/is
Priority to IL133868A priority patent/IL133868A/en
Priority to NO20000123A priority patent/NO329918B1/no
Priority to HK00105603A priority patent/HK1026429A1/xx
Priority to CY20061101705T priority patent/CY1105805T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE9702680A 1997-07-11 1997-07-11 New formulation SE9702680D0 (sv)

Priority Applications (38)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation
TW087109890A TW585764B (en) 1997-07-11 1998-06-19 Pharmaceutical composition comprising a nucleotide analogue and one or more glass forming additives
US09/125,165 US6130208A (en) 1997-07-11 1998-06-29 Formulation containing a nucleotide analogue
PCT/SE1998/001287 WO1999002542A1 (en) 1997-07-11 1998-06-29 New formulation
PT98934017T PT1000079E (pt) 1997-07-11 1998-06-29 Nova formulação
SK1836-99A SK285766B6 (sk) 1997-07-11 1998-06-29 Farmaceutická kompozícia obsahujúca nukleotidový analóg a spôsob jej prípravy
DK98934017T DK1000079T3 (da) 1997-07-11 1998-06-29 Hidtil ukendt formulering
CZ20000083A CZ298110B6 (cs) 1997-07-11 1998-06-29 Lyofilizovaná, ve spreji susená nebo vakuove susená farmaceutická kompozice a zpusob její výroby
CN98807089A CN1263533A (zh) 1997-07-11 1998-06-29 新型制剂
HU0002622A HU226489B1 (en) 1997-07-11 1998-06-29 Stabilised pharmaceutical compositions containing nucleotide analogs
DE69836023T DE69836023T2 (de) 1997-07-11 1998-06-29 Neue Formulierung
EEP200000022A EE04119B1 (et) 1997-07-11 1998-06-29 Külmkuivatamiseks sobiv ravimkoostis ja selle valmistamise meetod
IL13386898A IL133868A0 (en) 1997-07-11 1998-06-29 New formulation pharmaceutical composition comprising a nucleotide analogue and one or more glass forming additives
RU2000103216/14A RU2216330C2 (ru) 1997-07-11 1998-06-29 Фармацевтическая композиция, содержащая нуклеотидный аналог, и способ ее приготовления
AU83625/98A AU8362598A (en) 1997-07-11 1998-06-29 New formulation
ZA985669A ZA985669B (en) 1997-07-11 1998-06-29 New formulation
CNA2006100092846A CN1864696A (zh) 1997-07-11 1998-06-29 新型制剂
ES98934017T ES2273425T3 (es) 1997-07-11 1998-06-29 Nueva formulacion.
IDW20000028A ID24716A (id) 1997-07-11 1998-06-29 Formulasi baru
NZ502073A NZ502073A (en) 1997-07-11 1998-06-29 Pharmaceutical composition suitable for freeze drying comprising a nucleotide analogue and glass forming modifying agents
KR1020007000205A KR100786654B1 (ko) 1997-07-11 1998-06-29 신규 제제
BR9810703-8A BR9810703A (pt) 1997-07-11 1998-06-29 Composição farmacêutica, e, processos para a preparação da mesma, e para tratar um distúrbio de agregação de plaqueta
UA2000010491A UA65576C2 (uk) 1997-07-11 1998-06-29 Фармацевтична композиція, що містить нуклеотидний аналог і спосіб її приготування
JP2000502063A JP4950380B2 (ja) 1997-07-11 1998-06-29 新規な製剤
PL337970A PL192768B1 (pl) 1997-07-11 1998-06-29 Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie
EP98934017A EP1000079B1 (en) 1997-07-11 1998-06-29 New formulation
AT98934017T ATE340801T1 (de) 1997-07-11 1998-06-29 Neue verbindungen
SI9830865T SI1000079T1 (sl) 1997-07-11 1998-06-29 Nova formulacija
TR2000/00006T TR200000006T2 (tr) 1997-07-11 1998-06-29 Yeni formülasyon.
CA002295628A CA2295628C (en) 1997-07-11 1998-06-29 Stable formulations comprising a nucleotide and a freeze drying additive
ARP980103182A AR013157A1 (es) 1997-07-11 1998-06-30 Composicion farmaceutica que incluye un analogo nucleotido y proceso para su preparacion
MYPI98003170A MY116421A (en) 1997-07-11 1998-07-10 New formulation
SA98190328A SA98190328B1 (ar) 1997-07-11 1998-07-21 تركيبة تحتوي على مشابه النكليوتيد nucleotide
IS5331A IS2439B (is) 1997-07-11 1999-12-30 Stöðug efnablanda sem felur í sér kirnishliðstæðuog aukefni til frostþurrkunar
IL133868A IL133868A (en) 1997-07-11 2000-01-03 A pharmaceutical preparation containing nucleic acid analogues and one or more glass-forming additives
NO20000123A NO329918B1 (no) 1997-07-11 2000-01-10 Farmasoytisk preparat, samt fremgangsmate til fremstilling derav
HK00105603A HK1026429A1 (en) 1997-07-11 2000-09-05 New formulation
CY20061101705T CY1105805T1 (el) 1997-07-11 2006-11-27 Νεος σχηματισμος

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation

Publications (1)

Publication Number Publication Date
SE9702680D0 true SE9702680D0 (sv) 1997-07-11

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation

Country Status (36)

Country Link
US (1) US6130208A (sv)
EP (1) EP1000079B1 (sv)
JP (1) JP4950380B2 (sv)
KR (1) KR100786654B1 (sv)
CN (2) CN1864696A (sv)
AR (1) AR013157A1 (sv)
AT (1) ATE340801T1 (sv)
AU (1) AU8362598A (sv)
BR (1) BR9810703A (sv)
CA (1) CA2295628C (sv)
CY (1) CY1105805T1 (sv)
CZ (1) CZ298110B6 (sv)
DE (1) DE69836023T2 (sv)
DK (1) DK1000079T3 (sv)
EE (1) EE04119B1 (sv)
ES (1) ES2273425T3 (sv)
HK (1) HK1026429A1 (sv)
HU (1) HU226489B1 (sv)
ID (1) ID24716A (sv)
IL (2) IL133868A0 (sv)
IS (1) IS2439B (sv)
MY (1) MY116421A (sv)
NO (1) NO329918B1 (sv)
NZ (1) NZ502073A (sv)
PL (1) PL192768B1 (sv)
PT (1) PT1000079E (sv)
RU (1) RU2216330C2 (sv)
SA (1) SA98190328B1 (sv)
SE (1) SE9702680D0 (sv)
SI (1) SI1000079T1 (sv)
SK (1) SK285766B6 (sv)
TR (1) TR200000006T2 (sv)
TW (1) TW585764B (sv)
UA (1) UA65576C2 (sv)
WO (1) WO1999002542A1 (sv)
ZA (1) ZA985669B (sv)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038647A1 (ja) * 2004-10-05 2006-04-13 Asahi Kasei Pharma Corporation 補酵素の安定化方法およびその組成物
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
EP2471792B1 (en) 2009-08-28 2014-04-09 Daiichi Sankyo Company, Limited 3-(biaryloxy) propionic acid derivative
EA028885B1 (ru) 2009-11-11 2018-01-31 Чиези Фармачеутичи С.П.А. Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты)
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
US9622967B2 (en) * 2010-12-10 2017-04-18 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
JP5947316B2 (ja) 2011-02-09 2016-07-06 ザ メディシンズ カンパニー 肺高血圧症を処置するための方法
ES2657019T3 (es) 2011-08-17 2018-03-01 Samuel Shiber Catéter giratorio adaptativo para abrir vasos corporales obstruidos
EP2964233B1 (en) 2013-03-09 2021-12-15 Chiesi Farmaceutici S.p.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
BR112017014996A2 (pt) 2015-01-14 2018-03-20 Chiesi Farm Spa formulações farmacêuticas e recipientes selados
BR112019022676A2 (pt) 2017-06-23 2020-05-19 Chiesi Farm Spa método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar
TW202016088A (zh) 2018-06-19 2020-05-01 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (sv) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社　ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
ES2108425T3 (es) * 1993-02-10 1997-12-16 Astra Pharma Prod Analogos de atp sustituidos con n-alquilo-2.
RU2135176C1 (ru) * 1993-12-14 1999-08-27 Эли Лилли Энд Компани Водорастворенный комплекс включения соединений бензотиофена с водорастворимым циклодекстрином, способ его получения и фармацевтическая композиция
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
EP1491217A1 (en) * 1995-06-07 2004-12-29 The Regents Of The University Of California Stabilization of polynucleotide complexes
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
SE9604795D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation

Also Published As

Publication number Publication date
CA2295628A1 (en) 1999-01-21
NO329918B1 (no) 2011-01-24
IS5331A (is) 1999-12-30
SA98190328B1 (ar) 2006-08-15
US6130208A (en) 2000-10-10
HUP0002622A2 (hu) 2001-05-28
WO1999002542A1 (en) 1999-01-21
AU8362598A (en) 1999-02-08
UA65576C2 (uk) 2004-04-15
IL133868A0 (en) 2001-04-30
NO20000123L (no) 2000-03-03
DE69836023D1 (de) 2006-11-09
HK1026429A1 (en) 2000-12-15
IL133868A (en) 2010-05-17
PL337970A1 (en) 2000-09-11
EP1000079B1 (en) 2006-09-27
IS2439B (is) 2008-11-15
NO20000123D0 (no) 2000-01-10
BR9810703A (pt) 2000-08-08
CY1105805T1 (el) 2011-02-02
SK285766B6 (sk) 2007-07-06
DE69836023T2 (de) 2007-04-12
HU226489B1 (en) 2009-03-02
PT1000079E (pt) 2006-12-29
NZ502073A (en) 2001-09-28
CN1864696A (zh) 2006-11-22
CN1263533A (zh) 2000-08-16
KR100786654B1 (ko) 2007-12-21
MY116421A (en) 2004-01-31
ZA985669B (en) 1999-01-11
KR20010021647A (ko) 2001-03-15
CZ200083A3 (cs) 2000-06-14
RU2216330C2 (ru) 2003-11-20
EP1000079A1 (en) 2000-05-17
EE200000022A (et) 2000-10-16
PL192768B1 (pl) 2006-12-29
SK183699A3 (en) 2000-07-11
SI1000079T1 (sl) 2007-08-31
EE04119B1 (et) 2003-08-15
JP4950380B2 (ja) 2012-06-13
CA2295628C (en) 2008-07-29
ID24716A (id) 2000-08-03
CZ298110B6 (cs) 2007-06-27
ES2273425T3 (es) 2007-05-01
JP2001509512A (ja) 2001-07-24
DK1000079T3 (da) 2006-11-20
AR013157A1 (es) 2000-12-13
ATE340801T1 (de) 2006-10-15
HUP0002622A3 (en) 2002-04-29
TR200000006T2 (tr) 2000-07-21
TW585764B (en) 2004-05-01

Similar Documents

Publication Publication Date Title
SE9702680D0 (sv) New formulation
IL124674A0 (en) Piperazine derivatives pharmaceutical compositions containing the same and use thereof
ES2083595T3 (es) Derivados de indol que inhiben la biosintesis de leucotrienos.
BR9611175B1 (pt) compostos e composiÇÕes farmacÊuticas.
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
TR200000812T2 (tr) 2-metil-tieno- benzodiazepin formülasyonu.
NO20006323D0 (no) Glykopeptidderivater og farmasöytiske sammensetninger som inneholder disse
DK0937074T3 (da) Benzonaphthyridiner som bronkiale terapeutiske midler
NO980178D0 (no) Cyklo-oksygenase-inhibitor og amidin-derivatsalter, fremgangsmåte for fremstilling derav, anvendelse derav som legemidler, og farmasöytiske blandinger inneholdende slike derivater
ATE267602T1 (de) 2-methyl-thieno-benzodiazepin-formulierung
ES2131528T3 (es) Nuevos polipeptidos y su uso.
DK0633763T3 (da) Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug
ES2117976T3 (es) Preparacion de derivados n-acetil neuraminicos.
IT1243193B (it) Composizioni farmaceutiche orali a base di melatonina
DE69513157D1 (de) Heterofunktionelle mucoadhäsive galenische zusammensetzung
SE9604795D0 (sv) New pharmaceutical formulation
DK0842165T3 (da) Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
AU1192397A (en) Substituted thiazolines and their use for controlling animal pests
PT100001A (pt) Novos derivados glicosilicos inibidores da gluco-hidrolase uteis como agentes antidiabeticos
ES2091039T3 (es) Nuevos bis-fenil-hexenos.